moves to amend the bill on 1, line 3, by adding before the phrase "TO PREVENT" the phrase
"TO AMEND THE LAWS GOVERNING PRODUCTS LIABILITY ACTIONS,";

and on page 3, line 47-48, by adding the following between the lines:

"PART III. AMEND THE LAWS GOVERNING PRODUCTS LIABILITY ACTIONS
  SECTION 3.1 Chapter 99B of the General Statutes is amended by adding a new
  section to read:
  (a) Except as provided in subsection (b) of this section, in any product liability action
  against a manufacturer of a drug, if the drug that is alleged to have caused the harm was
  approved for safety and efficacy by the United States Food and Drug Administration, and the
  drug and its labeling were in compliance with the United States Food and Drug
  Administration's approval at the time the drug left the control of the manufacturer, there is a
  rebuttable presumption that the manufacturer did not fail to provide an adequate warning. This
  presumption may be rebutted by a preponderance of the evidence.
  (b) This section does not apply if the claimant proves that the manufacturer, at any time
  before the event that allegedly caused the harm, did any of the following:
  (1) Sold the drug in the United States after the effective date of an order of the
      United States Food and Drug Administration to remove the drug from the
      market, to withdraw its approval, or to substantially alter the terms of
      approval in a manner that would have avoided the claimant's alleged injury.
  (2) Intentionally, and in violation of applicable regulations as determined by
      final agency action, withheld from or misrepresented to the United States
      Food and Drug Administration information material to the approval or
      maintaining of approval of the drug, and such information is relevant to the
      harm which the claimant allegedly suffered.
  (3) Made an illegal payment to an official or employee of a government agency
      for the purpose of securing or maintaining approval of the drug.
SECTION 3.2. This section applies only to product liability claims alleging that a drug manufacturer failed to provide an adequate warning.

SECTION 3.3. Section 3.1 of this act becomes effective October 1, 2014, and applies to actions commenced on or after that date."